The E-LIFT trial was a 20-week, randomized, controlled, unblinded study that compared standard treatment for T2D (i.e., anti-diabetic medicines other than SGLT2 inhibitors) plus 10 mg empagliflozin to standard treatment without empagliflozin among 50 adults with T2D and NAFLD (36). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.